annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION
Cancer Prevention/Epidemiology
Display Time: 2:00 PM - 6:00 PM
Display Location: E450b
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E451b
CME credit: 1
Track(s): Cancer Prevention/Epidemiology
Kala Visvanathan, MD, MHS—Co-Chair
The Johns Hopkins University
Marie Wood, MD—Co-Chair
University of Vermont
Discussion
5:00 PM Judy Ellen Garber, MD, MPH (Abstracts #1509–1514)
Dana-Farber Cancer Institute
Discussion
5:15 PM Barnett S. Kramer, MD, MPH (Abstracts #1515–1520)
National Institutes of Health
Discussion
5:30 PM Dean Brenner, MD (Abstracts #1521–1524)
University of Michigan Medical Center
Discussion
5:45 PM To be determined
Brd. 1 Impact of early detection strategies on cancer mortality in germlineTP53
mutation carriers in Li-Fraumeni syndrome. (Abstract #1509)
A. Villani, U. Tabori, J. D. Schiffman, A. Shlien, H. Druker, A. Novokmet,
J. L. Finlay, D. Malkin
Brd. 2 PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics,
onco-phenotype, and molecular analysis. (Abstract #1510)
M. M. Patnaik, S. Khambatta, S. I. Robinson, R. L. Richardson, M. P. Goetz
Brd. 3 Prevalence of BRCA1 mutations among 284 women with triple-negative
breast cancer. (Abstract #1511)
F. Fostira, M. Tsitlaidou, H. Gogas, M. Pertesi, D. Yannoukakos, E. Bournakis,
V. Karavassilis, P. Skarlos, I. Konstantopoulou, G. Fountzilas
Brd. 4 Primary fallopian tube lesions in BRCA mutation carriers undergoing
risk-reducing surgery. (Abstract #1512)
F. Dao, G. Han, K. J. Park, G. J. Gardner, N. D. Kauff, R. R. Barakat, R. A. Soslow,
D. A. Levine, Memorial Sloan-Kettering Cancer Center
Brd. 5 Noncancer endpoints in BRCA1/2 carriers after risk-reducing salpingooophorectomy.
(Abstract #1513)
J. Cohen, L. Chiel, J. Stopfer, J. Powers, S. M. Domchek
Brd. 6 Characterization of new Ashkenazi Jewish founder mutations in MSH6
causing Lynch syndrome. (Abstract #1514)
L. Raskin, F. Schwenter, M. Freytsis, M. Tischkowitz, D. A. Levine, S. Narod,
S. Gallinger, G. Rennert, W. Foulkes, S. B. Gruber
Brd. 7 What size of tumors should we detect as early-stage lung cancers in CT
screening? Stage-size relationship in long-term repeated screening over 15
years. (Abstract #1515)
N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui,
M. Kusumoto, T. Tsuchida, H. Nishiyama, N. Moriyama
396